Literature DB >> 24302286

Integrating pharmacogenetic information and clinical decision support into the electronic health record.

Barry R Goldspiel1, Willy A Flegel, Gary DiPatrizio, Tristan Sissung, Sharon D Adams, Scott R Penzak, Leslie G Biesecker, Thomas A Fleisher, Jharana J Patel, David Herion, William D Figg, Juan J L Lertora, Jon W McKeeby.   

Abstract

Pharmacogenetics (PG) examines gene variations for drug disposition, response, or toxicity. At the National Institutes of Health Clinical Center (NIH CC), a multidepartment Pharmacogenetics Testing Implementation Committee (PGTIC) was established to develop clinical decision support (CDS) algorithms for abacavir, carbamazepine, and allopurinol, medications for which human leukocyte antigen (HLA) variants predict severe hypersensitivity reactions. Providing PG CDS in the electronic health record (EHR) during order entry could prevent adverse drug events. Medical Logic Module (MLM) programming was used to implement PG CDS in our EHR. The MLM checks to see if an HLA sequence-based gene test is ordered. A message regarding test status (result present, absent, pending, or test not ordered) is displayed on the order form, and the MLM determines if the prescriber can place the order, place it but require an over-ride reason, or be blocked from placing the order. Since implementation, more than 725 medication orders have been placed for over 230 patients by 154 different prescribers for the three drugs included in our PG program. Prescribers commonly used an over-ride reason when placing the order mainly because patients had been receiving the drug without reaction before implementation of the CDS program. Successful incorporation of PG CDS into the NIH CC EHR required a coordinated, interdisciplinary effort to ensure smooth activation and a positive effect on patient care. Prescribers have adapted to using the CDS and have ordered PG testing as a direct result of the implementation.

Entities:  

Keywords:  Clinical Decision Support; Computerized Prescriber Order Entry; Informatics; Patient Safety; Pharmacogenetics

Mesh:

Substances:

Year:  2013        PMID: 24302286      PMCID: PMC3994859          DOI: 10.1136/amiajnl-2013-001873

Source DB:  PubMed          Journal:  J Am Med Inform Assoc        ISSN: 1067-5027            Impact factor:   4.497


  23 in total

1.  CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network.

Authors:  M V Relling; T E Klein
Journal:  Clin Pharmacol Ther       Date:  2011-01-26       Impact factor: 6.875

2.  Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing.

Authors:  M V Relling; E E Gardner; W J Sandborn; K Schmiegelow; C-H Pui; S W Yee; C M Stein; M Carrillo; W E Evans; T E Klein
Journal:  Clin Pharmacol Ther       Date:  2011-01-26       Impact factor: 6.875

3.  The path to personalized medicine.

Authors:  Margaret A Hamburg; Francis S Collins
Journal:  N Engl J Med       Date:  2010-06-15       Impact factor: 91.245

4.  To replicate or not to replicate: the case of pharmacogenetic studies: Have pharmacogenomics failed, or do they just need larger-scale evidence and more replication?

Authors:  John P A Ioannidis
Journal:  Circ Cardiovasc Genet       Date:  2013-08

Review 5.  Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing.

Authors:  M A Martin; T E Klein; B J Dong; M Pirmohamed; D W Haas; D L Kroetz
Journal:  Clin Pharmacol Ther       Date:  2012-02-29       Impact factor: 6.875

6.  Allopurinol pharmacogenetics: assessment of potential clinical usefulness.

Authors:  Issam Zineh; Padmaja Mummaneni; Jenna Lyndly; Shashi Amur; Lois A La Grenade; Stephen H Chang; Hobart Rogers; Michael A Pacanowski
Journal:  Pharmacogenomics       Date:  2011-12       Impact factor: 2.533

7.  Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing.

Authors:  M S Hershfield; J T Callaghan; W Tassaneeyakul; T Mushiroda; C F Thorn; T E Klein; M T M Lee
Journal:  Clin Pharmacol Ther       Date:  2012-10-17       Impact factor: 6.875

8.  Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan.

Authors:  Pei Chen; Juei-Jueng Lin; Chin-Song Lu; Cheung-Ter Ong; Peiyuan F Hsieh; Chih-Chao Yang; Chih-Ta Tai; Shey-Lin Wu; Cheng-Hsien Lu; Yung-Chu Hsu; Hsiang-Yu Yu; Long-Sun Ro; Chung-Ta Lu; Chun-Che Chu; Jing-Jane Tsai; Yu-Hsiang Su; Sheng-Hsing Lan; Sheng-Feng Sung; Shu-Yi Lin; Hui-Ping Chuang; Li-Chen Huang; Ying-Ju Chen; Pei-Joung Tsai; Hung-Ting Liao; Yu-Hsuan Lin; Chien-Hsiun Chen; Wen-Hung Chung; Shuen-Iu Hung; Jer-Yuarn Wu; Chi-Feng Chang; Luke Chen; Yuan-Tsong Chen; Chen-Yang Shen
Journal:  N Engl J Med       Date:  2011-03-24       Impact factor: 91.245

9.  Electronic health record design and implementation for pharmacogenomics: a local perspective.

Authors:  Josh F Peterson; Erica Bowton; Julie R Field; Marc Beller; Jennifer Mitchell; Jonathan Schildcrout; William Gregg; Kevin Johnson; Jim N Jirjis; Dan M Roden; Jill M Pulley; Josh C Denny
Journal:  Genet Med       Date:  2013-09-05       Impact factor: 8.822

10.  The IMGT/HLA database.

Authors:  James Robinson; Jason A Halliwell; Hamish McWilliam; Rodrigo Lopez; Peter Parham; Steven G E Marsh
Journal:  Nucleic Acids Res       Date:  2012-10-17       Impact factor: 16.971

View more
  28 in total

1.  CSER and eMERGE: current and potential state of the display of genetic information in the electronic health record.

Authors:  Brian H Shirts; Joseph S Salama; Samuel J Aronson; Wendy K Chung; Stacy W Gray; Lucia A Hindorff; Gail P Jarvik; Sharon E Plon; Elena M Stoffel; Peter Z Tarczy-Hornoch; Eliezer M Van Allen; Karen E Weck; Christopher G Chute; Robert R Freimuth; Robert W Grundmeier; Andrea L Hartzler; Rongling Li; Peggy L Peissig; Josh F Peterson; Luke V Rasmussen; Justin B Starren; Marc S Williams; Casey L Overby
Journal:  J Am Med Inform Assoc       Date:  2015-07-03       Impact factor: 4.497

Review 2.  Incorporating Pharmacogenomics into Health Information Technology, Electronic Health Record and Decision Support System: An Overview.

Authors:  Abdullah Alanazi
Journal:  J Med Syst       Date:  2016-12-17       Impact factor: 4.460

Review 3.  Standardization can accelerate the adoption of pharmacogenomics: current status and the path forward.

Authors:  Kelly E Caudle; Nicholas J Keeling; Teri E Klein; Michelle Whirl-Carrillo; Victoria M Pratt; James M Hoffman
Journal:  Pharmacogenomics       Date:  2018-06-19       Impact factor: 2.533

4.  Pharmacogenomic clinical decision support design and multi-site process outcomes analysis in the eMERGE Network.

Authors:  Timothy M Herr; Josh F Peterson; Luke V Rasmussen; Pedro J Caraballo; Peggy L Peissig; Justin B Starren
Journal:  J Am Med Inform Assoc       Date:  2019-02-01       Impact factor: 4.497

Review 5.  Personalization and Patient Involvement in Decision Support Systems: Current Trends.

Authors:  S Quaglini; L Sacchi; G Lanzola; N Viani
Journal:  Yearb Med Inform       Date:  2015-08-13

6.  Impact of SLCO1B1 Pharmacogenetic Testing on Patient and Healthcare Outcomes: A Systematic Review.

Authors:  Jason L Vassy; Sojeong Chun; Sanjay Advani; Sophie A Ludin; Jason G Smith; Elaine C Alligood
Journal:  Clin Pharmacol Ther       Date:  2018-10-18       Impact factor: 6.875

7.  Clinical Informatics Researcher's Desiderata for the Data Content of the Next Generation Electronic Health Record.

Authors:  Timothy I Kennell; James H Willig; James J Cimino
Journal:  Appl Clin Inform       Date:  2017-12-21       Impact factor: 2.342

8.  Pragmatic and Ethical Challenges of Incorporating the Genome into the Electronic Medical Record.

Authors:  Adam A Nishimura; Peter Tarczy-Hornoch; Brian H Shirts
Journal:  Curr Genet Med Rep       Date:  2014-12-01

9.  Integrating Pharmacogenomics into Clinical Practice: Promise vs Reality.

Authors:  Jennifer L St Sauver; Suzette J Bielinski; Janet E Olson; Elizabeth J Bell; Michaela E Mc Gree; Debra J Jacobson; Jennifer B McCormick; Pedro J Caraballo; Paul Y Takahashi; Veronique L Roger; Carolyn R Rohrer Vitek
Journal:  Am J Med       Date:  2016-05-05       Impact factor: 4.965

Review 10.  Pharmacogenomics Implementation at the National Institutes of Health Clinical Center.

Authors:  Tristan M Sissung; Jon W McKeeby; Jharana Patel; Juan J Lertora; Parag Kumar; Willy A Flegel; Sharon D Adams; Ellen J Eckes; Frank Mickey; Teri M Plona; Stephanie D Mellot; Ryan N Baugher; Xiaolin Wu; Daniel R Soppet; Mary E Barcus; Vivekananda Datta; Kristen M Pike; Gary DiPatrizio; William D Figg; Barry R Goldspiel
Journal:  J Clin Pharmacol       Date:  2017-10       Impact factor: 3.126

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.